AxoGen, Inc. Announces 2015 Annual Shareholders' Meeting

ALACHUA, Fla., April 27, 2015 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company dedicated to peripheral nerve repair, announced today that it will hold its Annual Shareholders' Meeting on Thursday, May 28, 2015. The Meeting will take place at 1:00 pm ET at the following location:

Hyatt Regency Orlando International Airport - Orly Room

9300 Jeff Fuqua Blvd.

Shareholders may also attend the Meeting via phone or internet link as follows:

Phone: 1.877.317.6789 or 1.412.317.6789

Internet Link: https://www.virtualshareholdermeeting.com/axogen15

The Proxy Statement, with the accompanying Notice of Annual Meeting, and 2014 Annual Report on Form 10-K are available on the Company's website at http://ir.axogeninc.com/proxy-statements#.

Shareholders of record of the Company's common stock at the close of business on April 1, 2015 will be entitled to receive notice of and to vote at the Meeting.

AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen's portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard Nerve Connector, a porcine submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed nerves, and AxoGuard Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

Avance Nerve Graft is processed in the United States by AxoGen. AxoGuard Nerve Connector and AxoGuard Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed worldwide exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.

Cautionary Statement Concerning Forward-Looking Statements

This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, market size, product development, product potential, or regulatory activity. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2015/04/prweb12681186.htm

Lee Robert "Bob" Johnston Jr, CFO

With a Reader Account, it's easy to send email directly to the contact for this release. Sign up today for your free Reader Account!

Already have an account? Log in here.